Brossard company whose CARA System uses AI modules to analyse retinal fundus photographs for diabetic retinopathy, age-related macular degeneration and microvascular changes, licensed by Health Canada in 2026 as a medical device.
Canadian innovation builds a brighter tomorrow.
Brossard company whose CARA System uses AI modules to analyse retinal fundus photographs for diabetic retinopathy, age-related macular degeneration and microvascular changes, licensed by Health Canada in 2026 as a medical device.
Its legal notice gives DIAGNOS Inc.'s registered office at 7005 boulevard Taschereau, Brossard; federal corporation 324873-9 is Active and a distributing corporation. diagnosmedical.com
Health Canada issued a Class II medical device licence for the CARA System on July 23, 2026, allowing sales to Canadian optometrists. diagnosmedical.com
Received Saudi FDA marketing authorization for CARA's diabetic retinopathy and macular degeneration algorithms in August 2026, selling through distributor Kanhoor Medical. diagnosmedical.com
Closed an oversubscribed C$4.0M brokered private placement led by Centurion One Capital in December 2025. diagnosmedical.com
Products DIAGNOS publishes on its own site. Each card links to the page it was taken from.
AI retinal analysis
Company describes AI-powered analysis modules in one clinician-controlled workflow: CARA-AMDdetect for macular degeneration, CARA-DR for diabetic retinopathy, CARA-MVA for retinal microvascular analysis, image enhancement and a clinician workspace.
SourceAnnounced rounds only, newest first. Undisclosed amounts are shown as undisclosed.
Dec 9, 2025
Investors: Centurion One Capital (lead agent)
Publicly announced partnerships.
Research program in next-generation retinal AI, with DIAGNOS funding an industrial research chair ($500,000 over five years) alongside NSERC and Mitacs grants to ÉTS.
Local distributor of the CARA System in Saudi Arabia following the 2026 Saudi FDA authorization.
The Saudi Food and Drug Authority authorized CARA's diabetic retinopathy and macular degeneration algorithms; DIAGNOS will sell through local distributor Kanhoor Medical.
Health Canada licensed the CARA System on July 23, 2026, allowing DIAGNOS to sell its AI retinal analysis to Canadian optometrists. The company said it aims to file the new system with the FDA.
An NSERC Alliance grant of $725,734 and Mitacs Accelerate funding of $293,331 support an ÉTS research program with DIAGNOS. The grants fund the program, not DIAGNOS; the company contributes $500,000 over five years.
DIAGNOS closed a brokered private placement of units at $0.30 for gross proceeds of about C$4.0M, with Centurion One Capital as lead agent.
Sourced from the company's own pages or announcements.
André Larente
President and Chief Executive Officer
Yves-Stéphane Couture
Chief Operating Officer
Marc-André Massue
Chief Financial Officer
Terms the company uses about its own work.
Other companies in Digital Health & HealthTech.
Discover companies, track funding, explore career opportunities and stay informed about Canada’s growing tech ecosystem.